Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03223922 · ClinicalTrials.gov registry record · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
A NA study of Brain Metastases, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT03223922 is a NA study of Brain Metastases that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 24 participants, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03223922, a NA study of Brain Metastases, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a trial that evaluates the preservation of cognition and neuropsychiatric function following genu-sparing whole brain radiation in patients with brain metastases.
Conditions Studied
Interventions
- RADIATION whole brain radiation therapy
Study Locations (2)
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Maryland
- The SKCCC at Johns Hopkins - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2017-07-19 |
| Est. Completion | 2030-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03223922
The ClinicalTrials.gov registry entry for NCT03223922 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (89% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which whole brain radiation therapy is the first listed.
NCT03223922 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT03223922 about?
NCT03223922 is a clinical study titled "Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases". This is a trial that evaluates the preservation of cognition and neuropsychiatric function following genu-sparing whole brain radiation in patients with brain metastases.
What is the current status of trial NCT03223922?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2017-07-19. Estimated completion is 2030-12.
What conditions does trial NCT03223922 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT03223922?
The interventions under investigation include: whole brain radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT03223922?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03223922 being conducted?
This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
RECRUITING · NA
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
REMASTer: REcurrent Brain Metastases After SRS Trial
RECRUITING · NA
-
Development of MRF for Characterization of Brain Tumors After Radiotherapy
RECRUITING · NA
-
MeDex: No Perioperative Dexamethasone in Brain Metastases
RECRUITING · NA
-
A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.